A decade later, another MIT retreat explores factors behind slow adoption of technologies touted in the first – and how the barriers could be overcome to deliver higher-quality, more shortage-proof generic drugs.
The vision goes like this: drug manufacturers will build more resilient supply chains and prevent drug shortages by restoring US-based manufacturing, and they will do it by adopting advanced technologies that enable them to achieve higher quality while competing on price against India and China despite higher wages and greater environmental and worker protections in the US.
In support of this vision, the US Food and Drug Administration has worked to facilitate the use of continuous and...
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
